Cargando…

437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an infection with widely varying clinical severity. Severe COVID-19 was initially proposed to be secondary to cytokine storm syndrome (CSS). However, studies since showed that patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Amanda M, Souquette, Aisha, Agrawal, Mona, Wolf, Joshua, Gaur, Aditya, Allison, Kim J, Estepp, Jeremie, Allen, Emma, Thomas, Paul, Smallwood, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644557/
http://dx.doi.org/10.1093/ofid/ofab466.636
_version_ 1784610113707835392
author Green, Amanda M
Souquette, Aisha
Agrawal, Mona
Wolf, Joshua
Wolf, Joshua
Gaur, Aditya
Allison, Kim J
Estepp, Jeremie
Allen, Emma
Thomas, Paul
Smallwood, Heather
author_facet Green, Amanda M
Souquette, Aisha
Agrawal, Mona
Wolf, Joshua
Wolf, Joshua
Gaur, Aditya
Allison, Kim J
Estepp, Jeremie
Allen, Emma
Thomas, Paul
Smallwood, Heather
author_sort Green, Amanda M
collection PubMed
description BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an infection with widely varying clinical severity. Severe COVID-19 was initially proposed to be secondary to cytokine storm syndrome (CSS). However, studies since showed that patients with severe COVID-19 rarely display CSS cytokine phenotypes, and may have more limited inflammatory responses instead. METHODS: Prospective cohorts, aged 0-90 years of age who tested positive by polymerase chain reaction (PCR) for SARS-CoV-2 were enrolled from inpatient hospitals and outpatient testing centers in Memphis, TN from May 2020-January 2021. Longitudinal blood samples were obtained including acute, sub-acute and convalescent timepoints. Severity scores of asymptomatic, mild, moderate, and severe COVID-19 were assigned at time of convalescent assessment. Plasma was analyzed with a quantitative human magnetic 38-plex cytokine assay. RESULTS: : 169 participants were enrolled, including 8 asymptomatic, 117 mild, 22 moderate and 17 severe cases, and 5 children with post-COVID-19 multisystem inflammatory syndrome in children (MIS-C). All moderate and severe patients were hospitalized and received treatment (39%). Clear distinctions were seen between asymptomatic-mild cases and moderate-severe cases at acute timepoints and during disease progression for GCSF, IL-8, IL-10, IL-15, IL-1Ra, IP-10, MIP-1a, MIP-1β, and TGFα. There was a significant difference between participants who did and did not require hospitalization for acute timepoint levels of IL-10, IL-15, MIP-1 β and TGFα (p< 0.01). Only 4 participants with active COVID-19 were found to meet criteria for CSS (2%), only 3 of which were severe. MIS-C participants showed nearly universally elevated cytokine levels compared to those with active COVID-19. Temporal and severity associations of IL-10 and IP-10 [Image: see text] Figure 1. Temporal and severity associations of IL-10 and IP-10 Examples of differentiating cytokine profiles by severity and time. Among SARS-CoV-2 PCR positive participants, IL-10 and IP-10 displayed increased levels in their acute plasma samples as clinical severity increased [A,C]. IL-10 and IP-10 also showed distinct time-dependent responses (ln(Cytokine level (pg/mL)) that differentiated the more severe from the less severe groups [B,D]. CONCLUSION: Moderate and severe acute COVID-19 has a distinct cytokine profile from asymptomatic and mild cases, as detected from acute, subacute and convalescent plasma. DISCLOSURES: Joshua Wolf, MBBS, PhD, FRACP, Karius Inc. (Research Grant or Support) Joshua Wolf, MBBS, PhD, FRACP, Nothing to disclose Paul Thomas, PhD, Cytoagents (Consultant)Immunoscape (Consultant)
format Online
Article
Text
id pubmed-8644557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86445572021-12-06 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups Green, Amanda M Souquette, Aisha Agrawal, Mona Wolf, Joshua Wolf, Joshua Gaur, Aditya Allison, Kim J Estepp, Jeremie Allen, Emma Thomas, Paul Smallwood, Heather Open Forum Infect Dis Poster Abstracts BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an infection with widely varying clinical severity. Severe COVID-19 was initially proposed to be secondary to cytokine storm syndrome (CSS). However, studies since showed that patients with severe COVID-19 rarely display CSS cytokine phenotypes, and may have more limited inflammatory responses instead. METHODS: Prospective cohorts, aged 0-90 years of age who tested positive by polymerase chain reaction (PCR) for SARS-CoV-2 were enrolled from inpatient hospitals and outpatient testing centers in Memphis, TN from May 2020-January 2021. Longitudinal blood samples were obtained including acute, sub-acute and convalescent timepoints. Severity scores of asymptomatic, mild, moderate, and severe COVID-19 were assigned at time of convalescent assessment. Plasma was analyzed with a quantitative human magnetic 38-plex cytokine assay. RESULTS: : 169 participants were enrolled, including 8 asymptomatic, 117 mild, 22 moderate and 17 severe cases, and 5 children with post-COVID-19 multisystem inflammatory syndrome in children (MIS-C). All moderate and severe patients were hospitalized and received treatment (39%). Clear distinctions were seen between asymptomatic-mild cases and moderate-severe cases at acute timepoints and during disease progression for GCSF, IL-8, IL-10, IL-15, IL-1Ra, IP-10, MIP-1a, MIP-1β, and TGFα. There was a significant difference between participants who did and did not require hospitalization for acute timepoint levels of IL-10, IL-15, MIP-1 β and TGFα (p< 0.01). Only 4 participants with active COVID-19 were found to meet criteria for CSS (2%), only 3 of which were severe. MIS-C participants showed nearly universally elevated cytokine levels compared to those with active COVID-19. Temporal and severity associations of IL-10 and IP-10 [Image: see text] Figure 1. Temporal and severity associations of IL-10 and IP-10 Examples of differentiating cytokine profiles by severity and time. Among SARS-CoV-2 PCR positive participants, IL-10 and IP-10 displayed increased levels in their acute plasma samples as clinical severity increased [A,C]. IL-10 and IP-10 also showed distinct time-dependent responses (ln(Cytokine level (pg/mL)) that differentiated the more severe from the less severe groups [B,D]. CONCLUSION: Moderate and severe acute COVID-19 has a distinct cytokine profile from asymptomatic and mild cases, as detected from acute, subacute and convalescent plasma. DISCLOSURES: Joshua Wolf, MBBS, PhD, FRACP, Karius Inc. (Research Grant or Support) Joshua Wolf, MBBS, PhD, FRACP, Nothing to disclose Paul Thomas, PhD, Cytoagents (Consultant)Immunoscape (Consultant) Oxford University Press 2021-12-04 /pmc/articles/PMC8644557/ http://dx.doi.org/10.1093/ofid/ofab466.636 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Green, Amanda M
Souquette, Aisha
Agrawal, Mona
Wolf, Joshua
Wolf, Joshua
Gaur, Aditya
Allison, Kim J
Estepp, Jeremie
Allen, Emma
Thomas, Paul
Smallwood, Heather
437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups
title 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups
title_full 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups
title_fullStr 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups
title_full_unstemmed 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups
title_short 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups
title_sort 437. longitudinal plasma cytokine profiles differentiating covid-19 severity groups
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644557/
http://dx.doi.org/10.1093/ofid/ofab466.636
work_keys_str_mv AT greenamandam 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT souquetteaisha 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT agrawalmona 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT wolfjoshua 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT wolfjoshua 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT gauraditya 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT allisonkimj 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT esteppjeremie 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT allenemma 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT thomaspaul 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups
AT smallwoodheather 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups